Trading Signals: FOLD Stock Price Prediction and Forecast (Thu. May. 31, 2007 - Fri. Dec. 22, 2023)(Amicus Therapeutics Inc)
| FOLD latest price $9.7650 (1.88%) ($9.7650 - $9.7650) on Fri. May. 7, 2021. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 4.88% (three month average) | RSI | 49 | Latest Price | $9.7650(1.88%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | FOLD declines -0.2% a day on average for past five trading days. | Weekly Trend | FOLD declines -0.7% a week on average for past two weeks. | Market Behavior | Broad based rally for large cap. Broad based rally for small cap. | Correlated ETFs | Broad market will support FOLD advance at 0% a week (0% probability) IBB(57%) IWO(53%) IWM(50%) XBI(50%) IWC(49%) | Factors Impacting FOLD price | FOLD will decline at least -2.44% in a week (0% probabilities). VIXM(-31%) VXX(-14%) UUP(-12%) UNG(-6%) TLT(-4%) | | | | | Relative Volatility | | | | Market Trend Strength | -2.44% (StdDev 4.88%) | Hourly BBV | 0.8 () | Intraday Trend | 0% | | | |
|
Resistance Level | $9.88 | 5 Day Moving Average | $9.79(-0.26%) | 10 Day Moving Average | $9.92(-1.56%) | 20 Day Moving Average | $9.88(-1.16%) | To recent high | -51% | To recent low | 6.2% | Market Cap | $2.522b | | | | Amicus Therapeutics, Inc. is a biotechnology company focused on discovering, developing, and delivering medicines for people living with rare metabolic diseases. The company is committed to advancing and expanding a pipeline of medicines for rare metabolic diseases, including a rare disease gene therapy portfolio. Amicus Therapeutics has a portfolio of product opportunities including the first and only approved oral precision medicine for people living with Fabry disease who have amenable genetic variants; a novel, clinical-stage, treatment paradigm for Pompe disease; and a rare disease gene therapy portfolio. The company was founded on February 4, 2002 and is headquartered in Cranbury, NJ. |